Immune Peptides Compared: Thymosin Alpha-1 vs Thymalin vs LL-37 vs KPV
Four immune-related research peptides, four different jobs: thymic T-cell modulation (Thymosin Alpha-1, Thymalin), direct antimicrobial defense (LL-37) and anti-inflammatory signaling (KPV), with mechanism, evidence and honest limitations.
TL;DR: Four peptides, four different immune jobs
"Immune peptide" is not one category. These four act on completely different arms of immunity and are complementary research tools, not interchangeable ones. Thymosin Alpha-1 is a defined 28-amino-acid thymic immunomodulator that signals through Toll-like receptors on dendritic cells to push a Th1 T-cell response (PMID 14982877). It has the deepest human data of the four. Thymalin is not a single molecule but a thymus-derived peptide mixture studied for T-cell differentiation (PMID 33237528, 9637345); its evidence comes largely from one research group. LL-37 is the only human cathelicidin, a direct antimicrobial that also modulates immunity, and it is genuinely double-edged (pro- or anti-inflammatory depending on context) (PMID 27117377, 32509872). KPV is a three-residue anti-inflammatory fragment of alpha-MSH that inhibits NF-kB, and its anti-inflammatory action does not depend on the melanocortin receptors that mediate alpha-MSH's pigmentary and appetite effects (PMID 18061177, 12750433).
Search "immune peptides" and you get a jumble of very different molecules treated as if they do the same thing. They do not. This article compares the four immune-related research peptides we stock on the axes that actually separate them: what class each belongs to, what molecular target it hits, which direction it pushes the immune system, how well-defined the molecule is, and how strong the evidence is. It is a mechanism-and-evidence explainer for laboratory research context only, with no dosing, no protocols and no disease-treatment claims. Conditions such as hepatitis B or colitis are named solely to describe what published studies investigated.
At a Glance: The Four Peptides Side by Side
- Class
- Thymic immunomodulator
- Definition
- Defined 28-aa peptide
- Primary mechanism
- TLR/dendritic-cell, Th1 skew
- Evidence maturity
- Deepest human data (approved drug form in some countries)
- Class
- Thymic peptide complex
- Definition
- Heterogeneous thymus mixture
- Primary mechanism
- T-cell differentiation and cytokine modulation
- Evidence maturity
- Mostly single-group, preclinical + limited clinical
- Class
- Cathelicidin
- Definition
- Defined 37-aa peptide
- Primary mechanism
- Direct antimicrobial + immune modulation
- Evidence maturity
- Predominantly preclinical, double-edged
- Class
- Anti-inflammatory tripeptide
- Definition
- Defined 3-aa peptide
- Primary mechanism
- PepT1 uptake, NF-kB/MAPK inhibition
- Evidence maturity
- Predominantly preclinical (cell + rodent)
The single most important takeaway is in the "class" column: two of these tune adaptive T-cell immunity, one is a direct antimicrobial, and one is an inflammation dampener. They are not four versions of the same thing.
Thymosin Alpha-1: The Thymic Immunomodulator With the Deepest Data
Thymosin Alpha-1 (Ta1) is a synthetically produced 28-amino-acid polypeptide, a fragment of prothymosin alpha originally derived from thymus extract. Its research profile is immune restoration rather than direct pathogen killing.
TLR and dendritic-cell mechanism (PMID 14982877, 33362999)
Ta1 modifies, enhances and restores immune function across multiple immune cell subsets and pushes T-cell responses toward a Th1 profile (PMID 33362999). Mechanistically, it activates dendritic cells through a MyD88-dependent, Toll-like-receptor-mediated pathway, driving IL-12 production via p38 MAPK and NF-kB and establishing Th1-dependent antifungal immunity in vivo (PMID 14982877). A review of the thymalfasin drug form describes it signalling through Toll-like receptors on dendritic cells to stimulate immune-related cytokine production across immune deficiency, infection and cancer settings (PMID 27450734).
The reason Ta1 has the strongest human dataset of the four is its approved drug form, thymalfasin. As thymalfasin it enhances T-cell function, stimulates Th1 cytokines and activates NK cells, and in chronic hepatitis B trials a 1.6 mg twice-weekly regimen for six months produced a significantly higher sustained response than untreated controls (PMID 15482167). That is regulatory and clinical background, not a treatment claim about our research material: thymalfasin (brand Zadaxin) is a prescription drug in some countries and is not FDA-approved in the US, and those studies used it for specific approved or investigational indications, not general "immune boosting".
Synthetic 28-amino-acid immunomodulatory peptide. Approved as Zadaxin in 35+ countries for chronic hepatitis B and C. Studied in 30+ trials across 11,000+ subjects for immune modulation via TLR2/9 dendritic cell signaling.
Thymalin: A Thymic Peptide Complex, Not a Single Molecule
Thymalin is the odd one out on definition. It is not one characterized sequence but a low-molecular-weight peptide fraction isolated from calf thymus. That distinction matters for reproducibility, and it is the honest caveat that runs through everything below.
Thymic peptides of this class activate T-cell differentiation, T-cell recognition of peptide-MHC complexes and modulate lymphocyte cytokine output such as IL-2 and IFN, behaving as cytokine-modulating immunoregulators rather than single defined molecules (PMID 9637345). In an in-vitro study of human hematopoietic stem cells, Thymalin reduced the immature-cell markers CD44 and CD117 while raising the mature T-lymphocyte marker CD28 roughly 6.8-fold, indicating a push of intermediate progenitors toward mature CD28+ T cells (PMID 33237528).
Read Thymalin's evidence carefully
Much of Thymalin's mechanistic and clinical literature comes from a single research group (the Khavinson/Kuznik line of work), often in Russian-language journals, and the proposed molecular mechanisms (short peptides such as KE, EW and EDP binding DNA and histones) are hypothesized by that group rather than independently established. Treat Thymalin's story as preliminary and largely single-source, not as robust confirmed science.
Thymus-derived immune peptide developed by Prof. Khavinson. Restores T-cell function and thymic activity that naturally decline with age. Over 40 years of clinical use in Russia for immune support and anti-aging research.
LL-37: The Only Human Cathelicidin, and It Is Double-Edged
LL-37 is a 37-residue amphipathic, cationic alpha-helical peptide cleaved from the hCAP18 precursor, and it is the sole human cathelicidin. Unlike the thymic peptides, it acts directly on pathogens: it disrupts microbial membranes with broad-spectrum antibacterial, antiviral and antifungal activity, and it also works as a host-defense modulator through chemotaxis of immune cells and neutralization of bacterial LPS (PMID 27117377).
LL-37 is not uniformly beneficial (PMID 32509872)
LL-37 is genuinely context-dependent and double-edged. Depending on tissue and environment it can promote inflammation and anti-infective responses, or conversely inhibit inflammation, and in some models it has been associated with promoting carcinogenesis (PMID 32509872). This is not a peptide to frame as simply "good for immunity"; its direction of effect depends on the setting, which is exactly why it is studied so carefully.
Cathelicidin-derived antimicrobial peptide (37 amino acids). Researched for innate immunity, antimicrobial activity, and wound-healing pathways. ≥98% HPLC purity with Janoshik CoA.
KPV: A Melanocortin-Receptor-Independent Anti-Inflammatory
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH residues 11 to 13). Its research role is inflammation dampening, and its defining feature is that this activity does not run through the melanocortin receptors.
PepT1 uptake and melanocortin-independent action (PMID 18061177, 12750433)
KPV is taken up via the PepT1 di/tripeptide transporter in intestinal epithelial and immune cells, and at nanomolar concentrations it inhibits NF-kB and MAP-kinase signalling and lowers pro-inflammatory cytokine secretion; oral KPV reduced DSS- and TNBS-induced colitis in mice (PMID 18061177). Crucially, its anti-inflammatory effect is melanocortin-receptor-independent: it was not blocked by an MC3/4-receptor antagonist, failed to raise cAMP, and stayed active in mice with non-functional MC1-R (PMID 12750433). That is why KPV's anti-inflammatory activity does not run through the melanocortin receptors that mediate the pigmentary and appetite effects of the parent alpha-MSH peptide.
The honest limitation: KPV's strong data is cell-culture and mouse-model work. Human clinical evidence for a KPV anti-inflammatory outcome is essentially absent, so the colitis and cytokine findings should be read as preclinical mechanism, not a demonstrated human effect.
Anti-inflammatory tripeptide derived from alpha-MSH (positions 11-13). Inhibits NF-kB signaling, supports gut barrier integrity, and shows antimicrobial activity. A targeted approach to inflammation research without broad immunosuppression.
How They Actually Differ
Four separable axes explain why these are complementary tools rather than substitutes.
Functional class. Ta1 and Thymalin are thymic immunomodulators that tune and restore adaptive (T-cell) immunity; LL-37 is a direct antimicrobial plus immune modulator; KPV is an anti-inflammatory tripeptide studied in cell and animal models. LL-37's defining role in this comparison is direct antimicrobial host defense, whereas KPV is characterized primarily by inflammation-dampening signalling.
Direction of effect. Ta1 pushes toward Th1 activation (PMID 14982877), while Thymalin supports T-cell differentiation and maturation (PMID 33237528); KPV suppresses NF-kB-driven inflammation (PMID 18061177); LL-37 is bidirectional and can be pro- or anti-inflammatory depending on tissue and environment (PMID 32509872).
Molecular definition. Ta1 (28-aa), LL-37 (37-aa) and KPV (3-aa) are each single defined sequences; Thymalin is a heterogeneous thymus mixture (PMID 9637345). That difference drives how reproducibly each can be characterized.
Biological compartment. Ta1 and Thymalin come from thymus and adaptive-immunity biology; LL-37 is an innate-immunity effector from epithelial and neutrophil cathelicidin; KPV is a hormone fragment. Different compartments, so they answer different research questions.
No head-to-head, no ranking
These four have never been directly compared in a single study, so there is no evidence-based "which is best". Any comparison here is about mechanism and class, not a potency ranking. Evidence maturity also differs sharply: Ta1 has the deepest human data (via thymalfasin), Thymalin's is largely single-group, and LL-37 and KPV are predominantly preclinical.
Thymic T-cell immunomodulation research
Synthetic 28-amino-acid immunomodulatory peptide. Approved as Zadaxin in 35+ countries for chronic hepatitis B and C. Studied in 30+ trials across 11,000+ subjects for immune modulation via TLR2/9 dendritic cell signaling.
Thymus-derived immune peptide developed by Prof. Khavinson. Restores T-cell function and thymic activity that naturally decline with age. Over 40 years of clinical use in Russia for immune support and anti-aging research.
Antimicrobial host-defense research
Research Context and Handling
Thymosin Alpha-1, Thymalin, LL-37 and KPV are supplied strictly for laboratory research and are not intended for human consumption. This article gives no dosing, administration routes or reconstitution-for-use guidance; study quantities (for example the nanomolar cell-culture concentrations for KPV, or the thymalfasin hepatitis B regimen) belong to their cited studies and are not instructions. Verify identity and purity against a batch-specific third-party Certificate of Analysis. For the single-compound detail, see the Thymosin Alpha-1 explainer, the Thymalin vs Thymosin Alpha-1 comparison, the LL-37 overview and the KPV guide.
Frequently Asked Questions
This article is for research and educational purposes only. Mechanisms and study findings are described for scientific context; conditions are named only to describe what published research investigated, and approval status is stated as regulatory background. Nothing here is medical advice, a health claim, dosing guidance or a recommendation for use. The four featured peptides (Thymosin Alpha-1, Thymalin, LL-37 and KPV) are sold exclusively for laboratory research; comparison-only compounds such as alpha-MSH are not offered for sale.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include 19% VAT; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.